Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
84.96
-0.22 (-0.26%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Guardant Health Revenue
In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth. Guardant Health had revenue of $281.27M in the quarter ending December 31, 2025, with 39.37% growth.
Revenue (ttm)
$982.02M
Revenue Growth
+32.88%
P/S Ratio
11.35
Revenue / Employee
$391,868
Employees
2,506
Market Cap
11.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.04B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.34B |
| Mettler-Toledo International | 4.03B |
| Charles River Laboratories International | 4.02B |
| Exact Sciences | 3.25B |
| Revvity | 2.86B |
GH News
- 5 days ago - Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - Business Wire
- 7 days ago - Invesco Small Cap Equity Fund Q4 2025 Portfolio Review - Seeking Alpha
- 7 days ago - Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership - Business Wire
- 10 days ago - New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare - Business Wire
- 11 days ago - Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 12 days ago - Guardant Health, Inc. (GH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Business Wire
- 19 days ago - Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America - Business Wire